Bergeat D, et al. - In a large multicentric cohort, researchers aimed at evaluating the impact of adjuvant chemotherapy (AC) after pancreaticoduodenectomy (PD) for distal cholangiocarcinoma (DCC). They analyzed patients from five French centers who underwent PD for DCC between 2000 and 2015 and received AC (AC+ group) or surgery only (AC− group). Even after propensity score matching, findings suggest no survival benefit of adjuvant chemotherapy (mostly based on gemcitabine regimen) for DCC after PD.